Results 141 to 150 of about 110,071 (192)

Lipid-free, thermostable mRNA vaccines prepared using atomic layer deposition. [PDF]

J Pharm Sci
Coleman HJ, Rauch A, Langsfeld E, Anderson K, Parlikar U, Funke HH, Garcea RL, Randolph TW.   +7 more
europepmc   +1 more source

NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants. [PDF]

Hum Vaccin Immunother
Poh XY, Mah SYY, Yeoh AYY, Chavatte JM, Lim DRX, Tan CCY, Tang HL, Gandhi M, Rahman N, Rao S, Chia PY, Sadarangani SP, Chin YQ, Ng LFP, Renia L, Lin RTP, Lye DC, Wang LF, Tan CW, Young BE.   +19 more
europepmc   +1 more source

Harnessing the Potential of mRNA Vaccines Against Infectious Diseases. [PDF]

Microb Biotechnol
Rezk N, McClean S.
europepmc   +1 more source

Retraction Note: Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19. [PDF]

NPJ Vaccines
Akingbola A, Adegbesan A, Adegoke K, Idahor C, Mariaria P, Peters F, Salami RA, Ojo O, Nwaeze E, Abdullahi O, Chuku J.   +10 more
europepmc   +1 more source

Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors. [PDF]

J Immunother Cancer
Carrera-Justiz S, Aghaee M, Qdaisat S, Weidert F, Garcia GA, Fagman L, Zhang D, Stover B, Moor RSF, Xie C, Goldenberg E, von Roemeling C, Doonan B, Chardon-Robles J, Elliott L, Sawyer WG, Deleyrolle LP, Sahay B, Foster TP, Seligson ND, Rahman M, Ghiaseddin A, Castillo P, Lee JH, Silver NL, Doty A, Ligon JA, Milner RJ, Mitchell D, Mendez-Gomez H, Moore H, Sayour EJ.   +31 more
europepmc   +1 more source

Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. [PDF]

Cells
Zoroddu S, Bagella L.
europepmc   +1 more source

Developing of potential mRNA vaccines based on tumor antigens and immune subtypes of esophageal cancer. [PDF]

Transl Cancer Res
Zhang Z, Hou J, Wang Y, Jiang Y, Wang W, Zhao J, Jin G, Zhao L, Li Q.   +8 more
europepmc   +1 more source

Impact of pre-existing anti-replicase immunity on the efficacy of self-amplifying mRNA vaccines. [PDF]

Nat Commun
Cui X, Amelinck L, Gillon O, Catani JPP, Gao Y, Sun Q, De Sutter E, Vervaeke P, Snoeck J, Lienenklaus S, Saelens X, Zhong Z, Sanders NN.   +12 more
europepmc   +1 more source

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. [PDF]

Nature
Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, D3CODE Team, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH.   +61 more
europepmc   +1 more source

Health Technology Assessment of mRNA Vaccines: Clinical, Economic, and Public Health Implications. [PDF]

Vaccines (Basel)
Genovese G, Rizzo CE, Genovese C.
europepmc   +1 more source